However, IL-2 is not well tolerated systemically, resulting in the creation of Darleukin (L19IL2), a fusion protein of IL-2 to L19, a monoclonal antibody that targets an angiogenesis marker, allowing for preferential delivery of the IL-2 cytokine to tumor cells [36]. The gene discussed is IL2; the disease is neoplasm.